RPG Life Sciences Limited


RPG Life Sciences Limited

Health CarePharmaceuticals and Biotechnology
  • Price (INR)743.55
  • Today's Change20.15 / 2.81%
  • Shares traded63.37k
  • 1 Year change+26.78%
  • Beta1.1685
Data delayed at least 15 minutes, as of Mar 21 2023.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

RPG Life Sciences Limited is an India-based pharmaceutical company. The Company operates in the domestic and international markets in the formulations, generics, and synthetic active pharmaceutical ingredients (APIs) space. Its business portfolio includes domestic formulations, international formulations and APIs. Its domestic formulation business manufactures and markets-branded finished dosage formulations in India. The domestic formulations business has presence in over 10 therapeutic areas including nephrology, oncology, respiratory, vitamins and minerals, gastrointestinal and pain management, among others. The international formulations business operates in the generics and branded generics space across the regulated and emerging markets. Its branded generics space focuses on therapeutic areas, including nephrology, gastroenterology, and complex vertebral malformation (CVM) disorders. The API product line offers a range of synthetic APIs in the general therapeutic category.

  • Revenue in INR (TTM)4.98bn
  • Net income in INR648.10m
  • Incorporated2007
  • Employees1.17k
  • Location
    RPG Life Sciences LimitedRPG House463, Dr. Annie Besant Road, WorliMUMBAI 400030IndiaIND
  • Phone+91 2 224981650
  • Fax+91 2 224970127
  • Websitehttp://www.rpglifesciences.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Jagsonpal Pharmaceuticals Ltd2.25bn204.13m7.69bn--37.70--35.323.427.797.7985.90------------5.39--6.8560.3658.229.084.60--98.92--38.8515.778.4410.549.71-28.93109.13
NGL Fine-Chem Ltd2.82bn-817.29m7.77bn329.00------2.75-132.29-132.29457.23--------8,580,666.00--17.96--24.1813.7748.76-28.9514.83---63.53--2.9323.0824.42-12.0327.3722.93--
Medicamen Biotech Ltd1.25bn137.00m7.83bn357.0056.22--39.216.2711.0111.01100.53--------3,500,164.00--8.02--11.9751.2233.6610.9710.62--6.12--9.012.426.9622.8223.6229.990.00
Bliss GVS Pharma Ltd7.34bn871.47m7.88bn750.009.22--6.871.078.218.2169.11--------9,784,959.00--7.11--9.8748.3136.8713.1810.68--16.38--11.7929.5012.91-78.04-6.36-6.52-3.58
Bajaj Healthcare Ltd6.91bn569.04m9.08bn1.05k15.96--11.201.3220.6220.62250.20--------6,564,269.00--11.38--19.7026.4725.658.248.64--4.44----3.4924.14-14.1155.6150.96--
Suven Life Sciences Ltd151.49m-1.11bn10.48bn117.00------69.17-6.67-6.670.9369--------1,294,812.00---9.45---10.9276.6465.15-735.49-19.84---360.85-----12.12-53.49-69.08---8.33--
Themis Medicare Ltd3.54bn584.45m11.03bn1.15k18.90--16.093.1263.4163.41384.11--------3,091,841.00--7.88--13.0366.8659.4616.5110.95------6.3971.0711.78104.1335.4930.56--
RPG Life Sciences Limited4.98bn648.10m11.85bn1.17k18.27--14.772.3839.2039.20301.24--------4,275,708.00--10.28--14.9566.3661.7013.017.69--265.31--27.4313.117.4928.7033.61-15.5827.94
TTK Health Care Ltd7.04bn284.73m12.27bn2.59k43.08--29.271.7420.16448.26498.06--------2,718,869.00--5.08--8.3751.2656.704.053.76--1.52--34.3125.882.57-49.68-0.24633.7214.87
Morepen Laboratories Ltd14.22bn427.58m12.83bn2.38k30.00--18.180.90220.83670.836727.43--------5,980,358.00--8.25--17.0832.7233.953.015.86--24.75--0.0030.2021.044.7333.8946.89--
Solara Active Pharma Sciences Ltd14.24bn-240.60m13.07bn2.25k----14.790.9179-6.69-6.69391.54--------6,317,702.00--------41.68---1.70-----0.1553-----21.56---126.26------
Novartis India Ltd4.01bn549.70m13.75bn81.0025.01--22.813.4322.2622.26162.31--------49,497,530.00--3.13--3.9748.8657.4213.717.18--31.51--75.564.86-9.43-117.80---29.150.00
Hester Biosciences Ltd2.55bn298.19m14.27bn584.0047.49--27.565.5935.3335.33293.92--------4,370,908.00--9.77--12.1972.2070.7612.2717.84--3.05--24.009.6513.3814.2010.8025.9113.54
Supriya Lifescience Ltd5.07bn978.40m15.05bn--15.38--13.782.9712.1612.1663.00------------------59.74--19.30----6.36----37.54--22.60------
Alembic Ltd1.08bn1.43bn15.66bn305.0010.92--18.0014.455.595.594.22--------3,552,853.00--3.40--3.5268.6650.2174.3558.12--53.28--6.086.39-11.87-35.238.8420.1255.18
Data as of Mar 21 2023. Currency figures normalised to RPG Life Sciences Limited's reporting currency: Indian Rupee INR

Institutional shareholders

0.05%Per cent of shares held by top holders
HolderShares% Held
American Century Investment Management, Inc.as of 02 Mar 20237.48k0.05%
Motilal Oswal Asset Management Co. Ltd.as of 28 Feb 202345.000.00%
Data from 31 Dec 2022 - 28 Feb 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.